Wayne G. Brisbane, MD, Author at Grand Rounds in Urology

Wayne G. Brisbane, MD

University of California, Los Angeles

Los Angeles, California

Wayne G. Brisbane, MD, is an Assistant Professor of Urology at the University of California, Los Angeles. Dr. Brisbane received his undergraduate degree from Seattle Pacific University and his medical degree from Loma Linda University School of Medicine. He completed his internship in General Surgery and residency in Urology at the University of Washington. He also served as a Research fellow for the Center for Industrial and Medical Ultrasound. Dr. Brisbane completed his fellowship in Urologic Oncology at the University of California, Los Angeles.

His research includes advanced prostate cancer imaging with micro-ultrasound, MRI, and PSMA PET scans. Dr. Brisbane is particularly interested in using advanced imaging to guide prostate cancer focal therapy. He was awarded the prestigious Prostate Cancer Foundation Young-Investigator Award for his work involving micro-ultrasound.

Dr. Brisbane is involved in multiple clinical trials, including new treatment energies for prostate cancer focal therapy including use of the NanoKnife System (irreversible electroporation), HIFU (high-intensity focused ultrasound), and cryoablation. Dr. Brisbane is a member of the American Medical Association (AMA), American Urologic Association (AUA), American College of Surgeons (ACS), Society of Urologic Oncology (SUO), and Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC).

Talks by Wayne G. Brisbane, MD

WSAUA 2025: Micro-Ultrasound (Micro-US), MRI, and PSMA PET in Prostate Cancer: Whole-Mount Correlation Study

Wayne G. Brisbane, MD | Nov 2025

his whole-mount correlation study compares micro-ultrasound (Micro-US), multiparametric MRI, and PSMA PET for detecting and staging prostate cancer. Results show Micro-US performs comparably to MRI for lesion detection, while MRI remains superior for assessing extracapsular extension. PSMA PET adds complementary but not superior diagnostic value.

PET Tumor Board Case 5: A Case of a 77-year-old Prostate Cancer Patient with Ulcerative Colitis and Uncertain PET Findings

E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins, MD, PhD, Sherief H. Gamie, MD, PhD, Daniel P. Petrylak, MD and Andrew W. Hahn, MD | Aug 2025

Multidisciplinary case review shows how PSMA PET false positives can mimic nodal disease and alter prostate cancer management.

PET Tumor Board – Case 4: A Case of a 66-year old Male with Elevated PSA of 9.06 and MRI Showing PI-RADS Category 4 and 5

E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins, MD, PhD, Sherief H. Gamie, MD, PhD, Daniel P. Petrylak, MD and Andrew W. Hahn, MD | Aug 2025

E. David Crawford, MD, and the panel discuss a case of a 66-year-old with elevated PSA, MRI PIRADS 5 lesion, and PSA density of 0.11.

PET Tumor Board – Case 3: 62-year-old BRCA2-Positive Prostate Cancer Survivor with PSA Recurrence

E. David Crawford, MD, Wayne G. Brisbane, MD, Sean P. Collins, MD, PhD, Sherief H. Gamie, MD, PhD and Daniel P. Petrylak, MD | Aug 2025

E. David Crawford, MD, presents a case involving a 62-year-old BRCA2-positive prostate cancer survivor with PSA recurrence.

Artificial Intelligence for Improving Prostate Cancer Management

Wayne G. Brisbane, MD | Jul 2025

Wayne Brisbane, MD, explores the integration of AI in focal therapy for prostate cancer management at UCLA.